Splenic plasma cells can serve as a source of amyloidogenic light chains

Blood

Volumn 113, Issue 7, 2009, Pages 1501-1503

  Solomon, Alan ^a   Macy, Sallie D ^a   Wooliver, Craig ^a   Weiss, Deborah T ^a   Westermark, Per ^a,b  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY;

AMYLOIDOSIS; ARTICLE; BONE MARROW; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN DEPOSITION; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIGHT CHAIN; PLASMA CELL; PRIORITY JOURNAL; SPLEEN CELL; TISSUE SECTION;

EID: 61849101470     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-154484     Document Type: Article

References (23)

1. Solomon A, Weiss DT. Protein and host factors implicated in the pathogenesis of light chain amyloidosis. Amyloid. 1995;2:269-279.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59.
3. Abe M, Goto T, Kosaka M, Wolfenbarger D, Weiss DT, Solomon A. Differences in kappa to lambda (κ:λ) ratios of serum and urinary free light chains. Clin Exp Immunol. 1998;111:457-462.
4. Abe M, Goto T, Kennel SJ, et al. Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies. Am J Clin Pathol. 1993;100:67-74.
5. Davern S, Tang LX, Williams TK, et al. Immunodi-agnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol. 2008;130:702-711.
6. Murphy CL, Eulitz M, Hrncic R, et al. Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol. 2001;116:135-142.
7. Murphy CL, Wang S, Williams T, Weiss DT Solomon A. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol. 2006;412:48-62.
8. Solomon A, Weiss DT, Macy SD, Antonucci RA. Immunocytochemical detection of kappa and lambda light chain V region subgroups in human B-cell malignancies. Am J Pathol. 1990;137:855-862.
9. Sze DM, Toellner KM, García de Vinuesa C, Taylor DR, MacLennan CM. Intrinsic constraint of plasmablast growth and extrinsic limits of plasma cell survival. J Exp Med. 2000;192:813-821.
10. Shapiro-Shelef M, Calame K. Plasma cell differentiation and multiple myeloma. Curr Opin Immunol. 2004;16:226-234.
11. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol. 2005;5:230-242.
12. Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol. 2002;14:517-521.
13. Ellyard JI, Avery DT, Phan TG, Hare NJ, Hodgkin PD, Tangye SG. Antigen-selected, immuno-globulin-secreting cells persist in human spleen and bone marrow. Blood. 2004;103:3805-3812.
14. Comenzo RL, Getz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276-4282.
15. Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid. 2007; 14:261-269.
16. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexametha-sone for AL amyloidosis. N Engl J Med. 2007;357: 1083-1093.
17. Cohen AD, Zhou P, Chou J, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007;139:224-233.
18. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92:1351-1358.
19. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110:787-788.
20. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis; results of a phase 2 trial. Blood. 2007;109:492-496.
21. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109:465-470.
22. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93: 295-298.
23. Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood. 2008;111:4908-4915.